Shots:
- JenaValve Technology has launched Trilogy THV System to treat ssAR in pts at high or greater surgical risk & reported successful first cases across the US
- The System uses radiopaque locators to attach directly to native aortic leaflets without calcification, allowing stable implantation, precise alignment, reduced paravalvular regurgitation, & preserving future coronary access with its open-cell nitinol frame
- Additionally, Trilogy THV System is being further assessed in the ARTIST trial, currently enrolling, to evaluate its use beyond high-risk patients
Ref: Globenewswire | Image: JenaValve | Press Release
Related News: JenaValve’s Trilogy Transcatheter Heart Valve System Secures FDA Approval for Symptomatic, Severe Aortic Regurgitation (ssAR)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
